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Received December 12, 2012; accepted January 31, 2013AbstractBackground: The relationship between the various cytokine responses that occur during sepsis remains controversial. Emerging evidence in-
dicates that the proinflammatory and anti-inflammatory responses are regulated simultaneously from the beginning of sepsis. However, the roles
of the novel anti-inflammatory mediators annexin (Anx)A1 and lipoxin (LX)A4 and the proinflammatory cytokines neutrophil gelatinase-
associated lipocalin (NGAL) and macrophage inflammatory protein (MIP)-3a have been studied.
Methods: In this study, the plasma levels of AnxA1, LXA4, NGAL, MIP-3a, interleukin (IL)-8 and IL-6 in patients with sepsis were determined
on admission to the intensive care unit. The patients were classified into survivors and non-survivors based on their outcome on day 28.
Results: AnxA1 and LXA4 levels were decreased in sepsis patients compared with control patients, whereas the levels of the proinflammatory
cytokines MIP-3a, NGAL, IL-8, and IL-6 were elevated. Furthermore, a significantly higher level of MIP-3a was detected in nonsurviving
patients compared with surviving patients ( p < 0.05), whereas there were no significant differences between these two groups for the levels of
the other mediators. Correlation analysis demonstrated that only NGAL level was closely correlated with the level of IL-6. Univariate analysis
indicated that the levels of MIP-3a and IL-8 were independent factors associated with patient survival, but this was not confirmed by the
multivariate analysis.
Conclusion: AnxA1 and LXA4 plasma levels were found to be decreased in sepsis patients, whereas the levels of MIP-3a and NGAL were found
to be elevated. This warrants further study in order to determine the clinical implications of these changes.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Our understanding of the proinflammatory versus anti-
inflammatory immune responses during sepsis has rapidly
evolved in recent years. Recent studies have demonstrated
that proinflammatory and anti-inflammatory responses are
regulated simultaneously from the first moments of sepsis and
that signs of immunosuppression are also already present* Corresponding author. Dr. Hui-Chi Hsu, Division of General Medicine,
Department of Medicine, Taipei Veterans General Hospital, 201, Section 2,
Shih-Pai Road, Taipei 112, Taiwan, ROC.
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http://dx.doi.org/10.1016/j.jcma.2013.05.004during the acute stage of sepsis.1e5 Proinflammatory cyto-
kines, such as tumor necrosis factor (TNF)-a, interleukin (IL)-
1a, IL-1b, IL-12, interferon (IFN)-g, and IL-6, are necessary
to initiate an effective inflammatory process in patients with
sepsis.6,7 However, somewhat to the contrary, anti-
inflammatory cytokines such as IL-10, IL-13, IL-4, and
transforming growth factor (TGF)-b, together with cytokine
inhibitors such as soluble TNF receptor (sTNFR)-I, sTNFR-II,
and IL-1 receptor antagonist, as well as the soluble IL-1 re-
ceptor, are also significantly increased in the circulation of
patients with sepsis.8e12 When the above findings are
considered together, it is evident that sepsis does not progresshinese Medical Association. All rights reserved.
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highly dynamic biological process. Despite their important
role in the pathogenesis of sepsis, the role of cytokines as
prognostic factors for the prediction of patient outcome
remains to be established. Recent studies have reported that
persistently high or increasing levels of proinflammatory
cytokines (TNF-a, IL-1b, IL-6, and IL-12) and anti-
inflammatory cytokines (IL-10), as well as sTNFR-I,
sTNFR-II, IL-1 receptor antagonist, and soluble IL-1g are
found mostly in non-survivors.13e19 In addition, an early and
sustained anti-inflammatory profile, as defined by a high
IL-10:TNF-a ratio, has been found to be a compromising
factor with respect to the late survival of patients with severe
sepsis.20
Neutrophil gelatinase-associated lipocalin (NGAL) is an
endogenous bacteriostatic protein that is synthesized by renal
tubular epithelial cells, neutrophils, and macrophages;
furthermore, it is also a novel biomarker for the early diag-
nosis of acute kidney injury.21 Macrophage inflammatory
protein (MIP)-3a (also designated as chemokine CC ligand 20)
is a chemotactic factor that mediates the recruitment of
immature dendritic cells, mature dendritic cells, and profes-
sional antigen-presenting cells to sites of epithelial inflam-
mation.22 Annexin (Anx)A1 was originally identified as a
corticosteroid-regulated protein, and together with lipoxin
(LX)A4, they are both important endogenous anti-
inflammatory mediators.23e25 Both molecules mediate the
inhibition of leukocyte trafficking, the stimulation of mono-
cyte migration, and adherence and stimulation of macrophage
clearance of apoptotic leukocytes during the resolution phase
of inflammation.26e28 Nevertheless, it is still not clear whether
or not the circulating levels of these four novel mediators are
able to be used as biomarkers in the clinical setting of sepsis.
Therefore, we conducted this study to determine the plasma
levels of the two anti-inflammatory mediators AnxA1 and
LXA4 as well as various proinflammatory cytokines, namely
NGAL, MIP-3a, IL-8 and IL-6, in sepsis patients admitted to
an intensive care unit (ICU). These results were then used to
explore their prognostic value in terms of predicting patient
survival outcome.
2. Methods2.1. PatientsThis was a prospective, observational study that was per-
formed at a tertiary referral ICU from June 2008 to May
2010. The study was approved by the Ethics Committee of
the Taipei Medical University Hospital, and informed consent
was obtained from either the patients themselves or their next
of kin. Patients were recruited on a consecutive basis. Pa-
tients with a diagnosis of sepsis were screened for eligibility.
The inclusion criteria consisted of clinical suspicion of
infection and evidence of a systemic response to infection;
furthermore, these needed to fulfil at least two of four criteria
related to the presence of systemic inflammatory response
syndrome.292.2. Measurement of cytokines and mediatorsPeripheral blood samples were collected from patients on
the first day after admission to the ICU. Peripheral blood from
20 healthy persons was also collected as a normal control.
Peripheral blood was centrifuged at 250g for 10 minutes and
subsequently each plasma sample was stored at e80C until
analysis. The levels of cytokines and mediators were deter-
mined by enzyme-linked immunosorbent assay (ELISA) using
commercially available kits (IL-8, MIP-3a, NGAL, and IL-6:
R&D Systems Inc., Minneapolis, MN, USA; LXA4: Neogen
Corp., Lexington, KY, USA). The level of AnxA1 was deter-
mined as reported by Goulding et al.30 The limits of sensitivity
of the above commercial ELISA kits were as follows: IL-8:
<10 pg/mL; MIP-3a: <0.47 pg/mL; NGAL: <0.012 ng/mL;
IL-6: < 0.7 pg/mL; and lipoxin A4: <0.01 ng/mL.2.3. Statistical methodsAll statistical tests were performed using SPSS for Win-
dows (SPSS Inc., Chicago, IL, USA). The ManneWhitney
nonparametric test was used to compare continuous outcome
measures between the patients and controls, and between the
survivors and non-survivors. Spearman rank correlation was
used for estimating the correlation between variables. Logistic
regression was applied for univariate and multivariate analyses
to determine the risk factors regarding mortality. Variables
with p < 0.1 in univariate analyses were entered into multi-
variate analyses. A p value < 0.05 was regarded as statistically
significant in two-sided tests.
3. Results3.1. Patient characteristicsA total of 66 patients were recruited into this study; the
characteristics of these patients are shown in Table 1. The source
of sepsis was classified as pulmonary in 57 cases (87%),
gastrointestinal in four cases (6%), neurological in four cases
(6%), and urosepsis in one case (1%). In total, 27 patients (40%)
died within 28 days of admission to the ICU. Further analysis
showed that there was no significant difference in the Acute
Physiology and Chronic Health Evaluation (APACHE) II score
and the use of ventilators between nonsurviving and surviving
patients, whereas the nonsurviving patients showed an associ-
ation with more frequent usage of steroid treatment than the
surviving patients (66.7% vs. 36.8%; p < 0.05).
The plasma levels of proinflammatory cytokine and anti-
inflammatory mediators were examined in these sepsis patients
at the time of admission to the ICU. The patients were further
classified as survivors and non-survivors based on their outcome
on day 28 of the observation process. As shown in Table 2, on
admission to the ICU, both surviving and nonsurviving patients
showed significantly higher plasma levels of the proin-
flammatory cytokines IL-8, IL-6, and NGAL compared to the
control patients. However, a significant increase in MIP-3a
levels over those of the control patients was only observed in
Table 1
Patient characteristics.
Characteristics Total (n ¼ 66) Survivors (n ¼ 39) Non-survivors (n ¼ 27) p value*
No. 66 39 27
Age (y) 79 (44e96) 80.5 (44e96) 81 (50e95) 0.99
Male 50 (75.8) 30 (76.9) 20 (74.1) 0.791
BMI 21.9 (14.7e52.2) 20.8 (14.7e52.2) 22.0 (15.0e31.3) 0.87
APACHE II 21.5 (6e37) 22 (12e37) 21 (6e35) 0.2
Ventilator treatment 46 (70.8) 26 (68.4) 20 (74.1) 0.621
Steroid treatment 32 (49.2) 14 (36.8) 18 (66.7) 0.018
Hospital days 25 (4e163) 32.5 (10e163) 18 (4e100) 0.04
White blood cell counta 11,250 (920e29,010) 11,420 (6070e26,940) 10,140 (920e29,010) 0.788
Absolute neutrophil counta 10,058 (660e27,353) 10,478 (5487e23,815) 8908 (660e27,353) 0.421
C-reactive protein (mg/dL)a 9.3 (0.3e27.5) 9.0 (0.8e27.5) 12.8 (0.3e22.5) 0.507
Data are presented as n (%) or n (range) unless otherwise identified.
* Survivors versus non-survivors, by ManneWhitney U test.
APACHE II ¼ Acute Physiology and Chronic Health Evaluation II; BMI ¼ body mass index.
a Data are expressed as median (range).
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mediators AnxA1 and LXA4 were found to be decreased in
both the survivors and non-survivors compared to the control
patients. Further investigation demonstrated that there was a
significantly higher level of MIP-3a present in nonsurviving
patients compared to surviving patients ( p < 0.05), whereas
there were no significant differences in the levels of AnxA1,
LXA4, IL-8, NGAL, and IL-6 between the surviving and non-
surviving patients (Table 2). Further correlation analysis was
performedwith respect towhite blood cell counts and levels of c-
reactive protein, IL-8, IL-6,MIP-3a, andNGAL. Only the serum
level of NGALwas found to be closely correlatedwith the serum
level of IL-6 (r ¼ 0.43, p ¼ 0.009).
Univariate analysis showed that the significant factors
related to survival outcome were IL-8 level ( p ¼ 0.008) and
MIP-3a level ( p ¼ 0.021). However, these two factors were
not found to be significant independent factors when a
multivariate analysis was carried out (Table 3).
4. Discussion
This prospective study investigated the plasma levels of
anti-inflammatory and proinflammatory cytokines/mediatorsTable 2
Plasma levels of anti-inflammatory and proinflammatory cytokines in patients with
Characteristics Normal Survivors
No. 20 39
Annexin A1a 4.6 (0.5e14.4) 4.7 (0.2e3
Lipoxin A4a 277.9 (152.0e408.9) 149.0 (0e3
IL-8b 10.6 (4.1e34.4) 40.6 (3.7e
MIP-3ab 21.8 (15.3e71.7) 38.9 (7.1e
NGALa 78.4 (53.7e188.3) 191.8 (7.1e
IL-6b 1.4 (0.9e13.0) 62.7 (6.5e
Data are presented as median (range).
IL ¼ interleukin; MIP ¼ macrophage inflammatory protein; NGAL ¼ neutrophil
*Survivors versus non-survivors, by ManneWhitney U test.
**Versus normal: p < 0.01, by ManneWhitney U test.
a Measured as ng/mL.
b Measured as pg/mL.in sepsis patients on admission to the ICU. We demonstrated
that the plasma levels of the anti-inflammatory mediators
AnxA1 and LXA4 were both decreased in sepsis patients
compared to normal patients when they were admitted to the
ICU. However, the levels of the proinflammatory cytokines,
MIP-3a, NGAL, IL-8, and IL-6, were elevated. Our results
differ from previous studies in which it has been shown that
anti-inflammatory cytokines such as IL-10 are concurrently
elevated with proinflammatory cytokines in patients with
sepsis.8,9,11 However, consistent with our results, previous
studies have also proposed a biphasic model to explain the
pathogenesis of the most severe form of sepsis. In this
situation, an initial proinflammatory phase is followed by an
anti-inflammatory response (also termed as compensatory
anti-inflammatory response syndrome).31e33 It is not clear
why in this study the plasma levels of AnxA1 and LXA4 were
lower than the levels found in healthy individuals. One
possible explanation is the fact that the majority of our patients
were elderly with 79.3% being older than 65 years, and the
group as a whole having a median age of 79 years. Further-
more, the control group was not age-matched with the patient
group. Therefore, further investigation is needed to explore
whether being older is associated with lower plasma level ofsepsis.
Non-survivors p value*
27
8.2) 1.3 (0.1e42.1) 1.0
25) 170.5 (3e416) 0.540
1592.2)** 127.8 (16.2e2413.9)** 0.379
573.3) 79.5 (22.0e521.3)** 0.016
716.8)** 204.1 (0e878.2)** 0.918
454.7)** 127.9 (0e1824.7)** 0.176
gelatinase-associated lipocalin.
Table 3
Univariate and multivariate logistic regression analysis of prognostic factors for survival in sepsis patients.
Variable Univariate Multivariate
OR (95% CI) p value* OR (95% CI) p value*
Sex, female vs. male 1.17 (0.37e3.64) 0.791 e e
Ventilator treatment, yes vs. no 1.32 (0.44e3.96) 0.622 e e
Steroid treatment, yes vs. no 3.43 (1.22e9.67) 0.020 3.92 (0.11e136.20) 0.451
APACHE II (>20 vs. 20) 0.86 (0.30e2.51) 0.785 e e
Age (y) (>70 vs. 70) 1.16 (0.38e3.53) 0.789 e e
BMI (kg/m2; >20 vs. 20) 2.82 (0.83e9.57) 0.096 13.30 (0.22e818.15) 0.218
WBC (cells/mm3; >10,000 vs. 10,000) 0.32 (0.10e1.00) 0.051 0.08 (0.01e2.85) 0.164
CRP (mg/dL; >12 vs. 12) 1.96 (0.64e6.05) 0.240 e e
Annexin A1 (>2 vs. 2)a 0.53 (0.11e2.62) 0.438 e e
Lipoxin A4 (>150 vs. 150)a 1.29 (0.39e4.30) 0.683 e e
IL-8 (>125 vs. 125)b 5.81 (1.60e21.17) 0.008 0.778 (0.02e29.68) 0.893
MIP-3a (>50 vs. 50)b 4.71 (1.27e17.56) 0.021 13.11 (0.45e382.43) 0.135
NGAL (>200 vs. 200)a 1.06 (0.34e3.35) 0.918 e e
IL-6 (>70 vs. 70)b 2.57 (0.64e10.31) 0.183 e e
Data are presented as median (range).
APACHE ¼ Acute Physiology and Chronic Health Evaluation II; BMI ¼ body mass index; CRP ¼ C-reactive protein; IL ¼ interleukin; MIP ¼ macrophage
inflammatory protein; NGAL ¼ neutrophil gelatinase-associated lipocalin; OR ¼ odds ratio; WBC ¼ white blood cell count.
* yEnrolled for multivariate analysis if p < 0.05.
a Measured as ng/mL.
b Measured as pg/mL.
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with respect to elderly patients being more likely to be in an
immunocompromised state. Related to the above findings,
Kosicka et al reported that the plasma level of AnxA1 is
decreased in obese patients and that this contributes to the
chronic inflammatory phenotype observed in obesity.34 The
important role of AnxA1 in the normal defense mechanisms
was supported by an animal study using AnxA1-null mice,
where it was found that these mice were more prone to both
acute and chronic inflammatory reactions.35,36 Taken together,
the decrease in the plasma levels of AnxA1 and LXA4 in
sepsis patients on admission to ICU suggests that the AnxA1
and LXA4 levels in these sepsis patients are likely to be
associated with these patients being in an immunocompro-
mised state.
Consistent with previous studies,37e39 our results indicate
that the proinflammatory cytokines NGAL and MIP-3a are
elevated in the peripheral blood of sepsis patients on admission
to the ICU; this is in addition to there being increases in IL-8 and
IL-6.MIP-3a is responsible for the chemoattraction of immature
dendritic cells, effector/memory T cells and B cells to the skin
andmucosal surfaces.MIP-3a also plays an important role in the
pathogenesis of inflammatory diseases, such as rheumatoid
arthritis and cancer.40 In this study, to the best of our knowledge,
we are the first to demonstrate that the level of MIP-3a is
elevated in the circulation of sepsis patients on admission to the
ICU, and that, in addition to the above, the level of MIP-3a is
also significantly higher in patients who died within 28 days of
admission to the ICU. This suggests that MIP-3a is likely to be a
compromising factor with respect to the late survival of patients
with sepsis, although its prognostic value in terms of predicting
survival outcome was not supported by the multivariate anal-
ysis. Nevertheless, our study had a relatively low number of
cases and our findings warrant further study in this area.Excessive production of proinflammatory cytokines in
sepsis patients has been associated with multiple organ-system
dysfunction including acute kidney injury.41 However, at
present, there are no biomarkers to predict the development of
acute kidney injury before the increase of creatinine level is
identified. In this regard, we were interested in establishing
whether the plasma level of NGAL was elevated in sepsis
patients. Parallel to this, Shapiro et al reported recently that
increased plasma NGAL level is a promising novel biomarker
for predicting the development of acute kidney injury in pa-
tients with sepsis,42 which suggests that at least some of our
patients were at risk of developing acute kidney injury.
However, further studies are needed to confirm the role of
NGAL level in predicting the development of acute kidney
injury in sepsis patients. If confirmed, the finding will help
clinicians to design effective treatment strategies that should
help to prevent the development of acute kidney injury in
sepsis patients.
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